TEVA and MEDCL Related Headlines

Go Back

Feb 20, 2026 03:37PM Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizo
Oct 10, 2025 04:11PM FDA approves UZEDY for bipolar I disorder maintenance treatment
Oct 10, 2025 04:11PM Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
Oct 10, 2025 03:00PM FDA approves UZEDY for bipolar I disorder maintenance treatment
Oct 10, 2025 03:00PM FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

TEVA and MEDCL Related Press Releases

Go Back

Feb 20, 2026 03:37PM Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizo
Oct 10, 2025 04:11PM Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
Oct 10, 2025 03:00PM FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

TEVA and MEDCL Related SEC Filings

Go Back